{"title":"MEN1通过破坏CD44选择性剪接促进铁下垂抑制肺癌。","authors":"Ting Pan,Jiamei Zhu,Xuyan Wang,Dekun Tang,Ziming Wang,Yunqiao Yang,Yin Teng,Qianting Tian,Guixue Dan,Chaochun Chen,Dafang Yu,Mengyuan Liu,Houmei Wang,Tuo Zhang,Bing Guo,Tengxiang Chen,Bangming Jin","doi":"10.1158/0008-5472.can-25-0021","DOIUrl":null,"url":null,"abstract":"Ferroptosis is a characteristic form of cell death triggered by excessive iron-dependent reactive oxygen species (ROS) that plays an important role in suppressing tumor development. Here, we identified MEN1 as a driver of ferroptosis in lung cancer. MEN1 facilitated lipid ROS generation and sensitized lung cancer cells to ferroptosis by perturbing CD44 precursor messenger RNA (pre-mRNA) splicing. CD44 variant isoforms were highly expressed and correlated with poor prognosis in human lung cancers. Loss of Men1 profoundly accelerated the progression of mutant Kras driven lung adenocarcinoma (LUAD) and promoted the accumulation of CD44 variant isoforms. Mechanistically, MEN1 maintained a relatively slow RNA polymerase II (Pol II) elongation by controlling the release of PAF1 from the CD44 pre-mRNA, which in turn prevented the inclusion of CD44 variable exons (CD44v). Furthermore, CD44v6-interfering peptides effectively abrogated the growth and metastasis of established MEN1 deficient tumors by activating ferroptosis. Collectively, this study unveils a mechanism of tumor suppression based on MEN1 regulation of CD44 alternative splicing, ROS production, and ferroptosis induction.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"19 1","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.\",\"authors\":\"Ting Pan,Jiamei Zhu,Xuyan Wang,Dekun Tang,Ziming Wang,Yunqiao Yang,Yin Teng,Qianting Tian,Guixue Dan,Chaochun Chen,Dafang Yu,Mengyuan Liu,Houmei Wang,Tuo Zhang,Bing Guo,Tengxiang Chen,Bangming Jin\",\"doi\":\"10.1158/0008-5472.can-25-0021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ferroptosis is a characteristic form of cell death triggered by excessive iron-dependent reactive oxygen species (ROS) that plays an important role in suppressing tumor development. Here, we identified MEN1 as a driver of ferroptosis in lung cancer. MEN1 facilitated lipid ROS generation and sensitized lung cancer cells to ferroptosis by perturbing CD44 precursor messenger RNA (pre-mRNA) splicing. CD44 variant isoforms were highly expressed and correlated with poor prognosis in human lung cancers. Loss of Men1 profoundly accelerated the progression of mutant Kras driven lung adenocarcinoma (LUAD) and promoted the accumulation of CD44 variant isoforms. Mechanistically, MEN1 maintained a relatively slow RNA polymerase II (Pol II) elongation by controlling the release of PAF1 from the CD44 pre-mRNA, which in turn prevented the inclusion of CD44 variable exons (CD44v). Furthermore, CD44v6-interfering peptides effectively abrogated the growth and metastasis of established MEN1 deficient tumors by activating ferroptosis. Collectively, this study unveils a mechanism of tumor suppression based on MEN1 regulation of CD44 alternative splicing, ROS production, and ferroptosis induction.\",\"PeriodicalId\":9441,\"journal\":{\"name\":\"Cancer research\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":16.6000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/0008-5472.can-25-0021\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/0008-5472.can-25-0021","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer.
Ferroptosis is a characteristic form of cell death triggered by excessive iron-dependent reactive oxygen species (ROS) that plays an important role in suppressing tumor development. Here, we identified MEN1 as a driver of ferroptosis in lung cancer. MEN1 facilitated lipid ROS generation and sensitized lung cancer cells to ferroptosis by perturbing CD44 precursor messenger RNA (pre-mRNA) splicing. CD44 variant isoforms were highly expressed and correlated with poor prognosis in human lung cancers. Loss of Men1 profoundly accelerated the progression of mutant Kras driven lung adenocarcinoma (LUAD) and promoted the accumulation of CD44 variant isoforms. Mechanistically, MEN1 maintained a relatively slow RNA polymerase II (Pol II) elongation by controlling the release of PAF1 from the CD44 pre-mRNA, which in turn prevented the inclusion of CD44 variable exons (CD44v). Furthermore, CD44v6-interfering peptides effectively abrogated the growth and metastasis of established MEN1 deficient tumors by activating ferroptosis. Collectively, this study unveils a mechanism of tumor suppression based on MEN1 regulation of CD44 alternative splicing, ROS production, and ferroptosis induction.
期刊介绍:
Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research.
With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445.
Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.